These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37536449)

  • 1. Cystic fibrosis and chronic pulmonary infection with Pseudomonas aeruginosa: Is gross domestic product (GDP) involved?
    Moore JE; Millar BC
    J Infect; 2023 Oct; 87(4):e75-e77. PubMed ID: 37536449
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematic Cochrane Review of antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.
    Hurley MN; Smith S; Forrester DL; Smyth AR
    Paediatr Respir Rev; 2020 Nov; 36():109-111. PubMed ID: 33129669
    [No Abstract]   [Full Text] [Related]  

  • 3. [How should chronic Pseudomonas aeruginosa bronchial infection be treated in the course of cystic fibrosis?].
    Hubert D; Desmazes-Dufeu N; Dusser D
    Rev Mal Respir; 2003 Apr; 20(2 Pt 2):S129-35. PubMed ID: 12910145
    [No Abstract]   [Full Text] [Related]  

  • 4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis.
    Jackson L; Waters V
    J Cyst Fibros; 2021 Jan; 20(1):8-16. PubMed ID: 33172756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y; Sauty A; Roulet M
    Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applied pharmacokinetics in acute exacerbations of Pseudomonas aeruginosa pneumonia in cystic fibrosis.
    Fraser GL; Grimes GR; Valenti AJ
    J Pediatr; 1982 Nov; 101(5):792-4. PubMed ID: 7131162
    [No Abstract]   [Full Text] [Related]  

  • 13. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
    Saiman L; Cohen MB
    Arch Pediatr Adolesc Med; 2011 Sep; 165(9):867-8. PubMed ID: 21893653
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of resistant Pseudomonas aeruginosa with elective and rescue intravenous antibiotic regimens in children with cystic fibrosis.
    Smyth E; David TJ; Patel L; Ashcroft P; Sanyal D; Vyas J
    Int J Antimicrob Agents; 2005 Jul; 26(1):95-6. PubMed ID: 15970432
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary infection and antibiotic treatment in patients with cystic fibrosis.
    Kerrebijn KF; Mouton J
    Acta Univ Carol Med (Praha); 1990; 36(1-4):28-33. PubMed ID: 2130712
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A
    Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
    [No Abstract]   [Full Text] [Related]  

  • 19. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
    Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
    Infection; 1987; 15(5):403-6. PubMed ID: 3121519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-Pseudomonas aeruginosa (Pa) antibiotic therapy and cystic fibrosis].
    Bellon G; Gilly R
    Rev Mal Respir; 1991; 8(2):263. PubMed ID: 1907014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.